Project Description
Updates from the CBTP Lab
The lab team at the Children’s Brain Tumor Project is working at an unprecedented pace in order to advance cures. Our team is focused on two strategic paths forward: (1) basic research toward breakthrough discoveries, and (2) translational research that will enable us to bring those discoveries to clinic.
Improving How Success Is Measured After Pediatric Brain Tumor Surgery
June 1, 2026 - Dr. Mark Souweidane co-authored a national consensus study establishing standardized outcome measures for pediatric brain tumor surgery, helping improve research quality and patient care across institutions.
CBTP Welcomes Summer Interns 2026
February 1, 2026 - Weill Cornell Medicine investigators have received a $100,000 grant from the GC Global consortium to study diffuse pediatric brain tumors, including gliomatosis cerebri. The project will develop standardized tools combining imaging and molecular data to better understand how these tumors spread through the brain.
No Laughing Matter 2026 Honors Gretchen Scott
May 28, 2026 - The 2026 Comedy Gala will be held on October 22 at the New York Athletic Club, bringing together 300 distinguished guests in support of pediatric brain tumor research. This year’s gala will honor designer Gretchen Scott for her early and lasting connection to Elizabeth’s Hope and her support of our mission at the CBTP.
Dr. Souweidane Presents on Innovations in Surgical Oncology
May 20, 2026 - Dr. Souweidane was recently invited to present on advances in surgical neurooncology and the field’s shift toward more precise and innovative approaches at 3 national conferences/meetings.
AACR ADVOCACY DAYS 2026
May 14, 2026 -CBTP Program Director Cindy Campbell joined the American Association for Cancer Research (AACR) and colleagues to advocate for sustained federal investment in cancer research. They met with NYS representatives to highlight the importance of continued support for scientific discovery.
CED Trial Funding from Cure Starts Now
APRIL 15, 2026 -Dr. Mark Souweidane has received a grant from The Cure Starts Now Foundation and partners to support a Phase 1a clinical trial testing 177Lu-DTPA-omburtamab in children and young adults with DMG, including DIPG. This next-generation approach combines precision radioimmunotherapy with real-time imaging to evaluate safety, dosing, and drug distribution in the tumor.